Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | FLT1 | P17948 | 1/20 | 0.44 |
| ▸ | FLT4 | P35916 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 2/20 | 0.42 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27007635 | 0.84 | NPC1 (0.62) | NPC1RAB9ASMN1; SMN2FLT1FLT4 | |
| SCHEMBL788910 | 0.84 | ALDH1A1 (0.54) | NPC1RAB9AAAK1SMN1; SMN2RECQL | |
| SCHEMBL789057 | 0.84 | USP30 (0.54) | NPC1RAB9AAAK1SMN1; SMN2RECQL | |
| SCHEMBL29422481 | 0.84 | USP30 (0.54) | NPC1RAB9AAAK1SMN1; SMN2RECQL | |
| SCHEMBL3137559 | 0.82 | LMNA (0.48) | NPC1RAB9AAAK1SMN1; SMN2RECQL | |
| SCHEMBL1693101 | 0.82 | AAK1 (0.45) | NPC1RAB9AAAK1SMN1; SMN2RECQL | |
| SCHEMBL17680509 | 0.82 | POLB (0.53) | NPC1RAB9ASMN1; SMN2RECQLMAPT | |
| SCHEMBL27007664 | 0.82 | NPC1 (0.73) | NPC1RAB9ASMN1; SMN2FLT1FLT4 | |
| SCHEMBL277358 | 0.79 | AAK1 (0.43) | NPC1RAB9AAAK1SMN1; SMN2RECQL | |
| SCHEMBL4865164 | 0.77 | LMNA (0.54) | NPC1RAB9ASMN1; SMN2MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2616071-A2 | FATTY ACID SYNTHASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2013-07-24 | — | — | EP | disclosed |
| US-20130172384-A1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED | 2013-07-04 | — | — | US | disclosed |
| WO-2012037299-A2 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172384-A1 | FATTY ACID SYNTHASE INHIBITORS | FASN, FADS1, FADS2 | NPC1 1120/4885RAB9A 4098/4885AAK1 935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.